Phase I/II, open label study of sequential Taxotere (docetaxel) and Gleevec (imatinib mesylate) in hormone refractory prostate cancer.
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2011
At a glance
- Drugs Docetaxel; Imatinib
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 11 Jan 2011 Actual end date changed from Apr 2010 to May 2010 as reported by ClinicalTrials.gov.